Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Avadel Pharmaceuticals Stock Jumped Higher Today

By Brian Orelli, PhD – Updated Feb 21, 2020 at 3:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An infusion of cash is just what the doctor ordered.

What happened

Shares of Avadel Pharmaceuticals (AVDL -3.79%) are up 30% at 2:24 p.m. EST after the biotech sold 8,680,225 American depositary shares and 487,614 shares of Series A nonvoting convertible preferred shares for $7.09 each in a private placement, grossing the company $65 million. Shares of Avadel closed at $7.12 yesterday, so the investors didn't request much of a discount.

So what

Avadel is developing FT218, a controlled-release formula of sodium oxybate, as a treatment for narcolepsy. The drug is being tested in the phase 3 Rest-On clinical trial comparing FT218 to Xyrem, a sodium oxybate product from Jazz Pharmaceuticals (JAZZ -2.23%) that has to be dosed twice a night. As a controlled-release formula, FT218 only has to be taken once a night.

Avadel didn't really need the cash right now. The biotech ended the third quarter with $72.5 million in the bank, which Avadel estimated would "fund operations well into 2021." Nevertheless, smart companies raise capital when they can, not when they have to, and the added cash will give Avadel more firepower to launch FT218, assuming it's approved by the Food and Drug Administration.

Pen and magnifying glass on a balance sheet

Image source: Getty Images.

Now what

Results from the Rest-On clinical trial are expected in the second quarter of this year, so some of today's run-up is likely due to investors jumping in ahead of the data release. Biotech investment funds deciding to invest now are likely being viewed as an endorsement in Rest-On being successful.

At a market cap of less than $350 million, Avadel won't need much in the way of sales of FT218 to support that valuation, especially since Avadel expected to generate $55 million in revenue in 2019 from its sterile injectable hospital products and received FDA approval for a fourth product in December.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Avadel Pharmaceuticals plc Stock Quote
Avadel Pharmaceuticals plc
AVDL
$4.82 (-3.79%) $0.19
Jazz Pharmaceuticals plc Stock Quote
Jazz Pharmaceuticals plc
JAZZ
$127.67 (-2.23%) $-2.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.